ERBB2 and breast carcinoma: In summary, our study results showed a synergistic combination treatment effect of ruxolitinib and calcitriol in HER2-enriched subtype SKBR3 and TN subtype MDA-MB-468 breast cancer cells, but not in luminal A subtype MCF-7 cells in vitro.